Juniper Biomedical
Develops advanced therapies using a precise neuromodulation micro-implant to treat various pelvic health conditions, including incontinence, pain, and sexual dysfunction.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $1.0m | Grant | |
| Total Funding | 000k | ||
Related Content
RBI Medical is a healthcare startup that is primarily focused on developing treatments for Stress Urinary Incontinence (SUI), a condition that affects over 40 million patients in the United States. SUI is characterized by the involuntary loss of urine during physical activities such as laughing, coughing, sneezing, or exercising. This condition can significantly impact a patient's quality of life, leading to social isolation and potentially exacerbating other life-threatening diseases. The societal cost of SUI in the US alone is estimated to be over $13 billion.
RBI Medical's approach to treating SUI is through a method called Selective Neuromodulation. Traditional neuromodulation technologies stimulate large proximal nerves, which can be imprecise and potentially affect untargeted nerves or body systems. In contrast, Selective Neuromodulation is designed to be more precise and targeted, potentially reducing undesired side effects.
The company operates in the healthcare market, specifically in the segment of urinary incontinence treatment. Its business model revolves around the development, approval, and commercialization of its treatment for SUI. The company generates revenue through the sale of its treatment to healthcare providers who then administer it to patients.
Keywords: Healthcare, Stress Urinary Incontinence (SUI), Treatment Development, Selective Neuromodulation, Patient Quality of Life, Social Impact, Healthcare Market, Revenue Generation, Treatment Commercialization, Urinary Incontinence Treatment.